JP2015516949A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516949A5
JP2015516949A5 JP2015502339A JP2015502339A JP2015516949A5 JP 2015516949 A5 JP2015516949 A5 JP 2015516949A5 JP 2015502339 A JP2015502339 A JP 2015502339A JP 2015502339 A JP2015502339 A JP 2015502339A JP 2015516949 A5 JP2015516949 A5 JP 2015516949A5
Authority
JP
Japan
Prior art keywords
nanoparticle aggregate
aggregate according
biofilm
nanoparticle
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/056598 external-priority patent/WO2013144247A1/en
Publication of JP2015516949A publication Critical patent/JP2015516949A/ja
Publication of JP2015516949A5 publication Critical patent/JP2015516949A5/ja
Pending legal-status Critical Current

Links

JP2015502339A 2012-03-28 2013-03-27 オステオポンチンとカルシウムおよび/またはストロンチウム含有粒子とを含有するナノ粒子凝集体 Pending JP2015516949A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12161802.9 2012-03-28
EP12161802 2012-03-28
PCT/EP2013/056598 WO2013144247A1 (en) 2012-03-28 2013-03-27 Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles

Publications (2)

Publication Number Publication Date
JP2015516949A JP2015516949A (ja) 2015-06-18
JP2015516949A5 true JP2015516949A5 (cg-RX-API-DMAC7.html) 2016-06-02

Family

ID=48141914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502339A Pending JP2015516949A (ja) 2012-03-28 2013-03-27 オステオポンチンとカルシウムおよび/またはストロンチウム含有粒子とを含有するナノ粒子凝集体

Country Status (13)

Country Link
US (2) US20150044260A1 (cg-RX-API-DMAC7.html)
EP (1) EP2830647A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015516949A (cg-RX-API-DMAC7.html)
KR (1) KR20150004814A (cg-RX-API-DMAC7.html)
CN (1) CN104321073A (cg-RX-API-DMAC7.html)
AR (1) AR090569A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013241750A1 (cg-RX-API-DMAC7.html)
CA (1) CA2868684A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014002583A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491691A1 (cg-RX-API-DMAC7.html)
MX (1) MX2014011594A (cg-RX-API-DMAC7.html)
NZ (1) NZ700295A (cg-RX-API-DMAC7.html)
WO (1) WO2013144247A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
US12109284B2 (en) 2016-11-08 2024-10-08 Dentherapy Ltd Compositions comprising fluoride and calcium and method for preparing them
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020197887A1 (en) * 2019-03-22 2020-10-01 The Board Of Regents Of The University Of Oklahoma Surface-modified doped titanium dioxide nanoparticles and uses
CN111366733B (zh) * 2020-03-07 2022-02-08 浙江大学 骨桥蛋白作为靶分子在调节肠道菌群定植中的应用
JPWO2021193398A1 (cg-RX-API-DMAC7.html) * 2020-03-27 2021-09-30
GB202010987D0 (en) 2020-07-16 2020-09-02 Dentherapy Ltd Oral care compositions and methods
GB202110114D0 (en) 2021-07-14 2021-08-25 Dentherapy Ltd Oral care compositions for use in treaatment
WO2023187028A1 (en) * 2022-03-31 2023-10-05 Nadavia Holding Aps Mouthwash composition comprising one or more strontium salt
WO2025008636A1 (en) 2023-07-06 2025-01-09 Dentherapy Ltd Oral care compositions for use in the treatment of dental health conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259243B2 (en) * 2000-01-07 2007-08-21 Arla Foods Amba Process for isolation of osteopontin from milk
NZ507335A (en) 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
AU2004294673B2 (en) * 2003-12-01 2010-05-20 Arla Foods Amba Use of osteopontin in dental formulations
CA2632876A1 (en) * 2005-12-16 2007-06-21 Arla Foods Amba Bovine osteopontin formulations for the improvement of the wound healing process
WO2009010071A1 (en) * 2007-07-16 2009-01-22 Aarhus Universitet Osteopontin nanoparticles system for drug delivery
AU2012222312B2 (en) 2011-03-03 2017-06-08 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species

Similar Documents

Publication Publication Date Title
AR058519A1 (es) Particulas que interrumpen o impiden la adhesion bacteriana composiciones y metodos relacionados
JP2013253094A5 (cg-RX-API-DMAC7.html)
CL2017002549A1 (es) Uso de una composición de bismuto-tiol (bt), que sirve para preparar un medicamento útil para el tratamiento de una herida abierta que tiene o que está en riesgo de tener una infección de biopelícula bacteriana.
EP2373791A4 (en) COMPOSITIONS AND METHOD FOR TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND THE EXTINGUISHING OR BZW. DECIMATION OF STAPHYLOCOCCUS AUREUS ON SURFACES
JP2015502179A5 (cg-RX-API-DMAC7.html)
MY157928A (en) Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
AR090569A1 (es) Agregados de nanoparticulas que contienen osteopontina y particulas que contienen calcio y/o estroncio
NO20073559L (no) Nanopartiklulaere tacrolimus-formuleringer
RU2017104218A (ru) Система для введения композиции для ухода за полостью рта
EA201070036A1 (ru) Наноразмерные молочно-кислые бактерии
EA200870531A1 (ru) Покрытие для фильтра для улавливания частиц
WO2009117410A3 (en) Formation of nanostructured particles of poorly water soluble drugs and recovery by mechanical techniques
ATE542867T1 (de) Dispersion, enthaltend ceroxid und kolloidales siliciumoxid
Welch et al. Investigation of the antibacterial effect of mesoporous magnesium carbonate
Mahmoud et al. BAR-encapsulated nanoparticles for the inhibition and disruption of Porphyromonas gingivalis–Streptococcus gordonii biofilms
Fattah et al. Antimicrobial and antibiofilm activity of biosynthesized silver nanoparticles against beta-lactamase-resistant Enterococcus faecalis
Miyaji et al. Sustained antibacterial coating with graphene oxide ultrathin film combined with cationic surface-active agents in a wet environment
NO20080403L (no) Nanopartikulaere megestrolformuleringer
Lasserre et al. Influence of low direct electric currents and chlorhexidine upon human dental biofilms
Javedani Bafekr et al. In vitro antibacterial activity of ceftazidime, unlike ciprofloxacin, improves in the presence of ZnO nanofluids under acidic conditions
PH12021551308A1 (en) Antimicrobial compositions comprising modified clay and nonionic triblock copolymers
CN106587291A (zh) 一种氧化钇‑四氧化三铁复合纳米抑菌材料的制备与应用
Zhang et al. Antibacterial activity and biocompatibility of nanoporous titanium doped with silver nanoparticles and coated with n-acetyl cysteine
Krishnaraj et al. Microbial interactions at nanobiotechnology interfaces: molecular mechanisms and applications
BR112012006267A2 (pt) processo para produzir partículas de substrato orgânico ligadas a nanopartículas ferromagnéticas comutáveis, partículas de substrato para diagnóstico, uso de nanopartículas ferromagnéticas comutáveis, e, medicamento para o tratamento de hipertermia no corpo humano ou animal